收费全文 | 69549篇 |
免费 | 5654篇 |
国内免费 | 1947篇 |
耳鼻咽喉 | 972篇 |
儿科学 | 3131篇 |
妇产科学 | 399篇 |
基础医学 | 6203篇 |
口腔科学 | 887篇 |
临床医学 | 8694篇 |
内科学 | 13822篇 |
皮肤病学 | 692篇 |
神经病学 | 2888篇 |
特种医学 | 1197篇 |
外国民族医学 | 6篇 |
外科学 | 4536篇 |
综合类 | 11214篇 |
现状与发展 | 10篇 |
一般理论 | 2篇 |
预防医学 | 5502篇 |
眼科学 | 339篇 |
药学 | 6158篇 |
45篇 | |
中国医学 | 4372篇 |
肿瘤学 | 6081篇 |
2024年 | 135篇 |
2023年 | 1371篇 |
2022年 | 2188篇 |
2021年 | 2813篇 |
2020年 | 2487篇 |
2019年 | 2222篇 |
2018年 | 2278篇 |
2017年 | 2142篇 |
2016年 | 2714篇 |
2015年 | 3140篇 |
2014年 | 5474篇 |
2013年 | 5237篇 |
2012年 | 4482篇 |
2011年 | 4744篇 |
2010年 | 3800篇 |
2009年 | 3361篇 |
2008年 | 3001篇 |
2007年 | 2770篇 |
2006年 | 2378篇 |
2005年 | 2148篇 |
2004年 | 2210篇 |
2003年 | 1439篇 |
2002年 | 1184篇 |
2001年 | 1123篇 |
2000年 | 859篇 |
1999年 | 858篇 |
1998年 | 821篇 |
1997年 | 782篇 |
1996年 | 852篇 |
1995年 | 780篇 |
1994年 | 865篇 |
1993年 | 657篇 |
1992年 | 671篇 |
1991年 | 619篇 |
1990年 | 575篇 |
1989年 | 493篇 |
1988年 | 490篇 |
1987年 | 304篇 |
1986年 | 308篇 |
1985年 | 409篇 |
1984年 | 344篇 |
1983年 | 226篇 |
1982年 | 303篇 |
1981年 | 235篇 |
1980年 | 193篇 |
1979年 | 173篇 |
1978年 | 128篇 |
1977年 | 112篇 |
1976年 | 103篇 |
1975年 | 47篇 |
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献Background
Partial nephrectomy (PN) is generally favored for cT1 tumors over radical nephrectomy (RN) when technically feasible. However, it can be unclear whether the additional risks of PN are worth the magnitude of renal function benefit.Objective
To develop preoperative tools to predict long-term estimated glomerular filtration rate (eGFR) beyond 30 d following PN and RN, separately.Design, setting, and participants
In this retrospective cohort study, patients who underwent RN or PN for a single nonmetastatic renal tumor between 1997 and 2014 at our institution were identified. Exclusion criteria were venous tumor thrombus and preoperative eGFR <15 ml/min/1.73 m2.Intervention
RN and PN.Outcome measurements and statistical analysis
Hierarchical generalized linear mixed-effect models with backward selection of candidate preoperative features were used to predict long-term eGFR following RN and PN, separately. Predictive ability was summarized using marginal , which ranges from 0 to 1, with higher values indicating increased predictive ability.Results and limitations
The analysis included 1152 patients (13 206 eGFR observations) who underwent RN and 1920 patients (18 652 eGFR observations) who underwent PN, with mean preoperative eGFRs of 66 ml/min/1.73 m2 (standard deviation [SD] = 18) and 72 ml/min/1.73 m2 (SD = 20), respectively. The model to predict eGFR after RN included age, diabetes, preoperative eGFR, preoperative proteinuria, tumor size, time from surgery, and an interaction between time from surgery and age (marginal ). The model to predict eGFR after PN included age, presence of a solitary kidney, diabetes, hypertension, preoperative eGFR, preoperative proteinuria, surgical approach, time from surgery, and interaction terms between time from surgery and age, diabetes, preoperative eGFR, and preoperative proteinuria (marginal ). Limitations include the lack of data on renal tumor complexity and the single-center design; generalizability needs to be confirmed in external cohorts.Conclusions
We developed preoperative tools to predict renal function outcomes following RN and PN. Pending validation, these tools should be helpful for patient counseling and clinical decision-making.Patient summary
We developed models to predict kidney function outcomes after partial and radical nephrectomy based on preoperative features. This should help clinicians during patient counseling and decision-making in the management of kidney tumors. 相似文献Findings: A 30-year-old man with complete paraplegia used the HAL® for 1 month (10 sessions) using his remaining muscle activity, including hip flexor and upper limb activity. Electromyography was used to evaluate muscle activity of the gluteus maximus, tensor fascia lata, quadriceps femoris, and hamstring muscles in synchronization with the Vicon motion capture system. A HAL® session included a knee extension session with the hip flexor and voluntary gait with upper limb activity. After using the HAL® for one month, the patient’s manual muscle hip flexor scores improved from 1/5 to 2/5 for the right and from 2/5 to 3/5 for the left knee, and from 0/5 to 1/5 for the extension of both knees.
Conclusion/clinical relevance: Knee extension sessions with HAL®, and hip flexor and upper-limb-triggered HAL® ambulation seem a safe and feasible option in a patient with complete paraplegia due to spinal cord injury. 相似文献